Compugen Ltd
NASDAQ:CGEN

Watchlist Manager
Compugen Ltd Logo
Compugen Ltd
NASDAQ:CGEN
Watchlist
Price: 1.41 USD -2.76% Market Closed
Market Cap: 126.3m USD
Have any thoughts about
Compugen Ltd?
Write Note

Intrinsic Value

CGEN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one CGEN stock under the Base Case scenario is 1 USD. Compared to the current market price of 1.41 USD, Compugen Ltd is Overvalued by 29%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CGEN Intrinsic Value
1 USD
Overvaluation 29%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Compugen Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CGEN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CGEN?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Compugen Ltd

Provide an overview of the primary business activities
of Compugen Ltd.

What unique competitive advantages
does Compugen Ltd hold over its rivals?

What risks and challenges
does Compugen Ltd face in the near future?

Summarize the latest earnings call
of Compugen Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Compugen Ltd.

Provide P/S
for Compugen Ltd.

Provide P/E
for Compugen Ltd.

Provide P/OCF
for Compugen Ltd.

Provide P/FCFE
for Compugen Ltd.

Provide P/B
for Compugen Ltd.

Provide EV/S
for Compugen Ltd.

Provide EV/GP
for Compugen Ltd.

Provide EV/EBITDA
for Compugen Ltd.

Provide EV/EBIT
for Compugen Ltd.

Provide EV/OCF
for Compugen Ltd.

Provide EV/FCFF
for Compugen Ltd.

Provide EV/IC
for Compugen Ltd.

Show me price targets
for Compugen Ltd made by professional analysts.

What are the Revenue projections
for Compugen Ltd?

How accurate were the past Revenue estimates
for Compugen Ltd?

What are the Net Income projections
for Compugen Ltd?

How accurate were the past Net Income estimates
for Compugen Ltd?

What are the EPS projections
for Compugen Ltd?

How accurate were the past EPS estimates
for Compugen Ltd?

What are the EBIT projections
for Compugen Ltd?

How accurate were the past EBIT estimates
for Compugen Ltd?

Compare the revenue forecasts
for Compugen Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Compugen Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Compugen Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Compugen Ltd compared to its peers.

Compare the P/E ratios
of Compugen Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Compugen Ltd with its peers.

Analyze the financial leverage
of Compugen Ltd compared to its main competitors.

Show all profitability ratios
for Compugen Ltd.

Provide ROE
for Compugen Ltd.

Provide ROA
for Compugen Ltd.

Provide ROIC
for Compugen Ltd.

Provide ROCE
for Compugen Ltd.

Provide Gross Margin
for Compugen Ltd.

Provide Operating Margin
for Compugen Ltd.

Provide Net Margin
for Compugen Ltd.

Provide FCF Margin
for Compugen Ltd.

Show all solvency ratios
for Compugen Ltd.

Provide D/E Ratio
for Compugen Ltd.

Provide D/A Ratio
for Compugen Ltd.

Provide Interest Coverage Ratio
for Compugen Ltd.

Provide Altman Z-Score Ratio
for Compugen Ltd.

Provide Quick Ratio
for Compugen Ltd.

Provide Current Ratio
for Compugen Ltd.

Provide Cash Ratio
for Compugen Ltd.

What is the historical Revenue growth
over the last 5 years for Compugen Ltd?

What is the historical Net Income growth
over the last 5 years for Compugen Ltd?

What is the current Free Cash Flow
of Compugen Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Compugen Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Compugen Ltd

Current Assets 114.8m
Cash & Short-Term Investments 112.7m
Receivables 2.1m
Non-Current Assets 8.7m
Long-Term Investments 3.1m
PP&E 3.9m
Other Non-Current Assets 1.6m
Current Liabilities 27.8m
Accounts Payable 11.4m
Accrued Liabilities 447k
Other Current Liabilities 15.9m
Non-Current Liabilities 35.3m
Other Non-Current Liabilities 35.3m
Efficiency

Earnings Waterfall
Compugen Ltd

Revenue
59.9m USD
Cost of Revenue
-9.3m USD
Gross Profit
50.6m USD
Operating Expenses
-40m USD
Operating Income
10.6m USD
Other Expenses
-9m USD
Net Income
1.6m USD

Free Cash Flow Analysis
Compugen Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CGEN Profitability Score
Profitability Due Diligence

Compugen Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional 1-Year Revenue Growth
ROE is Increasing
31/100
Profitability
Score

Compugen Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

CGEN Solvency Score
Solvency Due Diligence

Compugen Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Average Altman Z-Score
64/100
Solvency
Score

Compugen Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CGEN Price Targets Summary
Compugen Ltd

Wall Street analysts forecast CGEN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CGEN is 5.1 USD with a low forecast of 4.04 USD and a high forecast of 7.35 USD.

Lowest
Price Target
4.04 USD
187% Upside
Average
Price Target
5.1 USD
262% Upside
Highest
Price Target
7.35 USD
421% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CGEN?

Click here to dive deeper.

Dividends

Compugen Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for CGEN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Compugen Ltd Logo
Compugen Ltd

Country

Israel

Industry

Life Sciences Tools & Services

Market Cap

126.2m USD

Dividend Yield

0%

Description

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Contact

Holon
Azrieli Center, 26 Harokmim St. Bldg D
+97237658585.0
www.cgen.com

IPO

2000-08-01

Employees

73

Officers

CEO, President & Director
Dr. Anat Cohen-Dayag Ph.D.
Chief Scientific Officer
Dr. Eran Ophir Ph.D.
Senior Vice President of Technology Innovation
Dr. Zurit Levine Ph.D.
Vice President of Preclinical Development
Dr. Pierre Ferre Ph.D.
Chief Financial Officer
Mr. David Silberman CPA
Head of Investor Relations & Corporate Communications
Ms. Yvonne Naughton
Show More
General Counsel & Corporate Secretary
Mr. Eran Ben Dor
Vice President of Human Resources
Ms. Dorit Amitay
Senior VP & Senior Advisor of Data and Informatics Solutions
Dr. Yaron Turpaz M.B.A., Ph.D.
Vice President Research and Discovery
Rivka Schwartz
Show Less

See Also

Discover More
What is the Intrinsic Value of one CGEN stock?

The intrinsic value of one CGEN stock under the Base Case scenario is 1 USD.

Is CGEN stock undervalued or overvalued?

Compared to the current market price of 1.41 USD, Compugen Ltd is Overvalued by 29%.

Back to Top